Krystal Biotech (KRYS) Non-Current Assets (2016 - 2026)

Krystal Biotech has reported Non-Current Assets for 11 years, with the latest figure at $441.0 million in Q2 2026.

• Non-Current Assets for Q2 2026 came in at $441.0 million, up 48.46% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.4 billion (up 21.41% YoY), and the FY2025 annual result was $309.2 million, down 1.47% from the prior year.
• Non-Current Assets improved to $441.0 million in Q2 2026, from $377.2 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $441.0 million in Q2 2026 and troughed at $172.6 million in Q2 2022.
• A 5-year average of $257.5 million and a median of $243.0 million in 2024 frame the typical range for Non-Current Assets.
• The largest YoY upside for Non-Current Assets was 380.95% in 2022 against a maximum downside of 5.08% in 2022.
• A 5-year view of Non-Current Assets shows it stood at $174.7 million in 2022, then jumped by 31.93% to $230.4 million in 2023, then jumped by 36.17% to $313.8 million in 2024, then slipped by 1.47% to $309.2 million in 2025, then surged by 42.63% to $441.0 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $441.0 million in Q2 2026, $377.2 million in Q1 2026, and $309.2 million in Q4 2025.